Logo

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

Share this

Innovent Report Results of Dual Regimen in P-III ORIENT-32 Study as 1L Therapy for Advanced HCC

Shot:    

  • The P-III ORIENT-32 involves assessing of Tyvyt (sintilimab) + Byvasda (bevacizumab- biosimilar) vs sorafenib in a ratio (2:1) for 1L treatment of patients with advanced HCC
  • The study resulted in meeting its 1EPs of PFS and OS- the safety profile is consistent with prior studies- and no new safety signals were identified. Following the IDMC recommendation- Innovent to review the results with NMPA’s CDE in China
  • Tyvyt is a type of IgG4 mAb- that binds to PD-1 molecules on the surface of T-cells- blocking the PD-1 pathway and reactivates T-cells to kill cancer cells. The company is evaluating Tyvyt in 20+ studies across multiple cancer indications globally

­ Ref: Innovent | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions